Takeda picks first woman as CEO of centuries-old drugmaker
Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.
BioSpace2h
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...
Takeda’s next CEO is a familiar face in Massachusetts biotech scene
When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant.
Takeda 9-Month EPS Rises, Revises FY24 Outlook, Julie Kim To Be New CEO
Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026. Kim ...
Takeda gains after FY24 guidance raise, CEO transition
Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.
ジャパンタイムズ12h
Takeda picks first female CEO of centuries-old drugmaker
Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...